Actively Recruiting

Phase Not Applicable
Age: 45Years - 70Years
FEMALE
Healthy Volunteers
NCT06873971

Er:YAG Laser Combined With Vaginal Estriol for Genitourinary Syndrome of Menopause

Led by University of Nove de Julho · Updated on 2026-04-23

60

Participants Needed

1

Research Sites

55 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Chronic hypoestrogenism in postmenopausal women significantly impacts the urogenital epithelium, leading to Genitourinary Syndrome of Menopause (GSM) and increasing susceptibility to gynecological infections due to vaginal pH elevation. Therapies using the Erbium:YAG (Er:YAG) 2940nm laser and low dose topical estrogen have demonstrated efficacy in improving vaginal trophism and restoring microbiota balance. This randomised, double-blind clinical study aims to assess the effects of combining Er: YAG laser therapy with vaginal estriol compared with estriol therapy alone in postmenopausal women with GSM. Sixty patients will be recruited and randomly assigned to two groups. All participants will receive low-dose topical estrogen therapy (estriol cream ) for 14 days, followed by twice-weekly applications until completing three laser sessions at four-week intervals. Group 1 (Sham) will receive the laser with minimal fluence (0.5J/cm²) applied to maintain blinding (auditory cues) below the threshold for biological tissue, while Group 2 , will undergo active laser treatment. Inclusion criteria include age 45-70 years, vaginal pH ≥5, absence of hormone therapy or energy-based intimate treatments for 180 days, and moderate vaginal atrophy symptoms (SCORE \>4). Exclusion criteria include abnormal cervicalvaginal cytology in the last six months, corticosteroid therapy within 90 days, and BMI ≥35kg/m². Assessments will occur at Baseline, 30 days after each laser session and 4 months after the third laser application. The primary outcome is the Vaginal Health Index (VHI), while secondary outcomes include GSM symptom evaluation via the Visual Analog Scale, vaginal microbiota analysis through 16S gene sequencing, and quality-of-life and sexual health questionnaires. Statistical analysis of the groups will be performed using SPSS version 22.0. For analytical statistics, repeated measures ANOVA will be used for continuous data, and non-parametric tests for repeated measures, such as the Friedman test, when appropriate. A p-value \<0.05 will be considered statistically significant.

CONDITIONS

Official Title

Er:YAG Laser Combined With Vaginal Estriol for Genitourinary Syndrome of Menopause

Who Can Participate

Age: 45Years - 70Years
FEMALE
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Postmenopausal women aged 45 to 70 years
  • Moderate symptoms of GSM (vaginal dryness, burning, pain during intercourse, or discharge) with a score of 4 or higher on a 0-10 scale
  • Vaginal pH of 5 or higher at baseline
  • No hormone replacement therapy (vaginal or systemic) in the previous six months
  • No vaginal moisturizer use in the previous 30 days
  • Able and willing to provide informed consent and follow study procedures
Not Eligible

You will not qualify if you...

  • Vaginal or vulvar energy-based treatments in the previous six months
  • Abnormal cervical cytology (ASCUS, LSIL, or HSIL) in the last six months
  • Systemic corticosteroid therapy in the last 90 days
  • Body mass index (BMI) of 35 kg/m² or higher
  • Abnormal uterine bleeding in the last 30 days
  • Vaginal surgery in the last 180 days or uterine prolapse grade II or higher
  • History of malignant tumors or vaginal radiotherapy
  • Severe liver or kidney disease, autoimmune disease, or severe psychiatric disorder

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Universidade Nove de Julho

São Paulo, São Paulo, Brazil, 01525-000

Actively Recruiting

Loading map...

Research Team

S

Stella Zamuner

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here